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Abstract
Purpose Multidrug resistance (MDR) impedes cancer treatment. Two efflux transporters from the ATP-binding cassette (ABC)
family, ABCB1 and ABCG2, may contribute to MDR by restricting the entry of therapeutic drugs into tumor cells. Although a
higher expression of these transporters has been correlated with an unfavorable response to chemotherapy, transporter expression
does not necessarily correlate with function. In this study, we characterized the pharmacological properties of [18F]AVT-011, a
new PET radiotracer for imaging transporter-mediated MDR in tumors.
Methods AVT-011 was radiolabeled with 18F and evaluated with PET imaging in preclinical models. Transport of [18F]AVT-011
by ABCB1 and/or ABCG2 was assessed by measuring its uptake in the brains of wild-type, Abcb1a/b−/−, and Abcg2−/− mice at
baseline and after administration of the ABCB1 inhibitor tariquidar (n = 5/group). Metabolism and biodistribution of [18F]AVT-
011 were also measured. To measure ABCB1 function in tumors, we performed PET experiments using both [18F]AVT-011 and
[18F]FDG in mice bearing orthotopic breast tumors (n = 7–10/group) expressing clinically relevant levels of ABCB1.
Results At baseline, brain uptake was highest in Abcb1a/b−/−mice. After tariquidar administration, brain uptake increased 3-fold
and 8-fold in wild-type and Abcg2−/− mice, respectively, but did not increase further in Abcb1a/b−/− mice. At 30 min after
injection, the radiotracer was > 90% in its parent form and had highest uptake in organs of the hepatobiliary system.
Compared with that in drug-sensitive tumors, uptake of [18F]AVT-011 was 32% lower in doxorubicin-resistant tumors with
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highest ABCB1 expression and increased by 40%with tariquidar administration. Tumor uptake of [18F]FDG did not significantly
differ among groups.
Conclusion [18F]AVT-011 is a dual ABCB1/ABCG2 substrate radiotracer that can quantify transporter function at the blood-
brain barrier and in ABCB1-expressing tumors, making it potentially suitable for clinical imaging of ABCB1-mediated MDR in
tumors.
Keywords Cancer . Multidrug resistance . PET imaging . ABCB1 . ABCG2
Introduction
Two efflux transporters from the ATP-binding cassette (ABC)
family, ABCB1 and ABCG2, are thought to contribute to multi-
drug resistance (MDR) in cancer [1].While these transporters help
protect the body from exposure to toxins in physiological condi-
tions, they recognize a large number of anticancer agents as sub-
strates and prevent their entry into tumor cells [2]. In clinical
studies, the expression of ABCB1/ABCG2 mRNA has been
shown to inversely correlate with response to chemotherapy in
hematological malignancies [3–5] and solid tumors [6]. Tumors
refractory to chemotherapy also have an increasedmRNA expres-
sion of ABCB1 and/or ABCG2 [3, 7, 8].
However, upregulation of mRNA expression in treatment-
refractory cancer does not necessarily imply that the transporters
confer clinical MDR. Only in a few cancers is the expression of
ABCB1 and/or ABCG2 proteins higher than that found in normal
tissues [9, 10]. Furthermore, clinical trials usingABCB1 inhibitors
to increase tumor uptake of chemotherapeutics had little success,
partly because patients were not always screened for MDR status
and partly because ABCB1 is not known to mediate MDR in
some of the tested cancers [1, 11]. Yet, MDR remains a major
impediment in cancer treatment [1], and current clinical practice
does not screen for MDR status or the development of MDR
during therapy. A method that identifies patients who might have
drug-resistant tumors due to transporters could potentially improve
clinical management of MDR by allowing oncologists to person-
alize drug selection and predict clinical response [1].
Measurements of transporter function, as opposed to mRNA
detection, may detect transporter-mediated MDR and thereby
predict therapeutic response [12]. Positron emission tomography
(PET) or single-photon emission computed tomography
(SPECT) imaging can non-invasively assess the function of
ABCB1 in vivo [11], which may provide insight into how this
transporter contributes to MDR in patients [1]. Typically, the
washout rate and tumor uptake of radiolabeled substrates have
been used as measures of transporter activity. For example, in
both mouse and human breast tumors, the washout rate of the
SPECT radiotracer [99mTc]sestamibi was 2- to 5-fold higher in
tumorswith high levels of ABCB1 than in thosewith basal levels
[13–16]. Tumor uptake of substrate radiotracers, including
[99mTc]sestamibi, [18F]fluoropaclitaxel, [11C]verapamil, and
(R)-[11C]verapamil, has also been used as a marker of ABCB1
function in drug-resistant cancers [17–20]. However, these sub-
strate radiotracers suffer from drawbacks, including lower quan-
titative accuracy of SPECT as compared with PET
([99mTc]sestamibi), low signal ratio (1.1–1.3) between tumors
with basal and high ABCB1 levels ([18F]fluoropaclitaxel,
[11C]verapamil, and (R)-[11C]verapamil), and extensive
radiometabolism ([18F]fluoropaclitaxel, [11C]verapamil, and
(R)-[11C]verapamil) [17, 20]. The ABCB1 inhibitor tariquidar
was also radiolabeled for PET imaging of ABCB1 in tumors
[20, 21], but there is conflicting evidencewhether it is transported
by ABCB1 [22, 23].
A PETsubstrate radiotracer with an 18F-label that addresses
some of these drawbacks would improve quantification of
transporter-mediated MDR. Here, we evaluated the pharma-
cological characteristics of a new 18F-labeled PET radiotracer,
[18F]AVT-011 ([2-(4-{2-[6-(2-[18F]fluoroethoxy)-7-methoxy-
3,4-dihydro-1H-isoquinolin-2-yl]ethyl}phenylcarbamoyl)-
4,5-dimethoxyphenyl]amide), for imaging MDR mediated by
ABC transporters in vivo. We developed a two-step
radiosynthesis procedure, and evaluated if the radiotracer is
transported by ABCB1 and ABCG2.We then tested its ability
to detect ABCB1-mediated MDR in vivo by measuring its
uptake in an orthotopic model of chemotherapy-resistant
breast cancer expressing clinically relevant levels of ABCB1.
Materials and methods
Chemicals and radiochemistry
Details regarding chemicals, inhibitor formulation, and syn-
thesis of [18F]AVT-011 are described in Supplemental
Methods. Synthesis was performed at two different sites:
University of California Los Angeles (UCLA) and Austrian
Institute of Technology (AIT).
Animal models
For substrate selectivity studies, female mice from three
models were used: wild-type (n = 5 mice; 25.2 ± 2.1 g; model
FVB), Abcb1a/b−/− (n = 5 mice; 22.3 ± 2.1 g), and Abcg2−/−
(n = 5 mice; 21.3 ± 1.5 g; Taconic Biosciences, USA). For
tumor uptake studies, female wild-type mice were used (n =
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27 mice; 24.7 ± 2.3 g, model FVB; Envigo). Tumors express-
ing different levels of ABCB1 were generated from Brca1−/
−;p53−/− FVB mouse mammary tumors as described before
[24, 25]. Briefly, orthotopic transplants were generated by re-
transplanting tumor pieces derived from the Brca1−/−;p53−/−
model into the mammary fat pads of wild-type mice to gener-
ate three groups of animals bearing tumors with basal, inter-
mediate, or high levels of ABCB1. The tumors with interme-
diate and highABCB1 levels were treated with doxorubicin (5
mg/kg i.v.) or with pegylated liposomal doxorubicin (PLD, 8
mg/kg i.v.), respectively [26]. Thawed pieces were used for re-
transplantation. Tumor volume was measured by calipers
using the V ¼ π6  l  w2 formula, where l is the tumor length
and w is the tumor width. PET imaging was performed on
tumors with volumes of 500–1000 mm3.
Animal experiments were conducted in accordance with ap-
proved protocols and guidelines from the Chancellor’s Animal
Research Committee at UCLA or in accordance with the
European Communities Council Directive (2010/63/EU), using
approved protocols from the Amt der Niederösterreichischen
Landesregierung.
PET imaging of transport activity at the blood-brain
barrier
To assess whether [18F]AVT-011 was a substrate of mouse
ABCB1 and ABCG2, we quantified its brain uptake in wild-
type, Abcb1a/b−/−, and Abcg2−/− mice with PET, before and
after treatment with tariquidar, an ABCB1 inhibitor. Mice were
anesthetized using 2% isoflurane in oxygen and cannulated on
the lateral tail vein. For inhibition studies, mice were injected i.v.
with 15 mg/kg tariquidar 30 min prior to injection of [18F]AVT-
011 (4.9 ± 2.3MBq). PET images were acquired on theG8 PET/
CT (Sofie Biosciences), Inveon PET (Siemens Medical
Solutions), or microPET Focus 220 (Siemens Medical
Solutions) calibrated scanner.Whole body PET/CT images were
acquired simultaneously in listmode for 120minwith a sequence
of 6 × 10 s, 4 × 60 s, 5 × 300 s, and 9 × 600 s.
PET imaging of transporter activity in MDR tumors
The ability of [18F]AVT-011 to detect ABCB1-mediatedMDR in
tumors was assessed by PET imaging of its uptake in breast
tumors implanted orthotopically in mice. Whole body PET im-
aging with [18F]AVT-011 was performed using a microPET
Focus 220 camera. Mice were anesthetized with 2–3.5%
isoflurane and injected via the tail vein with [18F]AVT-011 (5.3
± 2.1 MBq; 0.1 mL). One cohort of mice underwent 90-min
dynamic PET scans with [18F]AVT-011. During imaging, at
45 min after [18F]AVT-011 injection, tariquidar (15 mg/kg) was
administered as a short i.v. bolus over 1 min. PET data acquisi-
tion was then continued until 90 min after radiotracer injection.
Another cohort of animals bearing tumors from the basal and
high ABCB1–expressing groups underwent 90-min dynamic
PET scans without tariquidar injection. To determine whether
tariquidar administration potentially affected the kinetics of
[18F]AVT-011 in tumor tissue by another mechanism than
ABCB1 inhibition, we compared uptake in muscle tissue (a con-
trol region without ABCB1 expression) of animals that received
a mid-scan tariquidar injection versus those that did not (n = 3
mice/group).
For anatomical localization of tumors, [18F]FDG PET
scans were acquired the day before [18F]AVT-011 PET imag-
ing. Mice were fasted for a minimum of 6 h prior to [18F]FDG
injection. Mice had access to drinking water ad libitum.
[18F]FDG (5.7 ± 0.6 MBq, 0.1 mL) was injected intraperito-
neally and a 15-min static PET emission scan was initiated
60 min after [18F]FDG administration. Attenuation correction
was performed for tumor imaging. A 10-min transmission
scan using a rotating 57Co-source was acquired prior initiation
of the emission scans. Emission scans were performed with an
energy window of 250–750 keVand a timing window of 6 ns.
Metabolite and biodistribution analysis
Radiometabolism and biodistribution of [18F]AVT-011 were
measured ex vivo as described in Supplemental Methods.
Data analysis
PET data were decay-corrected and normalized to units of
percent injected dose per gram (%ID/g), and tissue time-
activity curves were generated using AMIDE [27] as de-
scribed in Supplemental Methods.
mRNA and protein quantification in tumors
Tumor expression of Abc1a/b was assessed using qPCR,
while ABCB1 levels were measured using Western blotting
as described in Supplemental Methods. Gene names are indi-
cated by italics (human: ABCB1, ABCG2; mouse: Abcb1a/b,
Abcg2), while protein names are indicated in non-italic, capi-
tal letters (human: ABCB1; mouse: ABCB1A, ABCB1B; hu-
man/mouse: ABCG2).
Statistical analysis
Statistical differences between two groups were analyzed by
two-tailed unpaired t tests while differences between multiple
groups were analyzed by 1-way, 2-way ANOVA, or Kruskal-
Wallis, and corrected for multiple comparisons with Dunnett’s
or Dunn’s test, respectively, using the Prism 7 software
(GraphPad Software, USA). All values are given as mean ±
standard deviation (SD), except for relative mRNA levels,
given as mean ± standard error of the mean (SEM).
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Results
AVT-011 can be labeled with 18F
18F-AVT-011 was produced at two different sites (UCLA and
AIT) using a two-step reaction involving (i) the synthesis of
[18F]fluoroethyl-tosylate by nucleophilic reaction of cyclotron-
produced [18F]fluoride with ethylene di(p-toluenesulfonate)
followed by (ii) reaction of [18F]fluoroethyl-tosylate with 6-O-
desmethyl tariquidar (Fig. 1). Crude product was purified by
semipreparative HPLC. The decay-corrected radiochemical
yields of [18F]AVT-011 based on starting [18F]fluoride were
3.7 ± 1.0% (n = 4 syntheses) at UCLA and 1.1 ± 0.6% (n = 8
syntheses) at AIT. Radiochemical yields were not optimized but
were sufficiently high for preclinical imaging. However, further
optimization would be required for clinical applications, such as
the performance of a single step [18F]fluorination reaction using
an appropriate tosylate precursor molecule. The total synthesis
timewas approximately 95min.Molar activities and radiochem-
ical purities of [18F]AVT-011 at the end of synthesis were 143 ±
31 GBq/μmol and 95 ± 2% (n = 4) at UCLA, and 99 ± 39 GBq/
μmol and 96 ± 3% at AIT. The identity of [18F]AVT-011 was
verified by HPLC co-injection with unlabeled AVT-011
(Supplemental Fig. 1).
[18F]AVT-011 is a substrate of mouse ABCB1A/B
and ABCG2
To determine whether [18F]AVT-011 is a substrate of mouse
ABCB1 and/or ABCG2, we assessed its uptake in the brains
of wild-type and transgenic mice lacking either transporter
(Fig. 2a). The brain was selected as the region to assess selec-
tivity because both transporters are co-expressed at the blood-
brain barrier and prevent substrate entry into the brain. The
uptake of [18F]AVT-011 in brain peaked within the first 5 min
before reaching a plateau for the remaining scan time (Fig.
2b). Brain uptake (area under the curve, AUC5–120 min) of
[18F]AVT-011 was 2-fold higher in Abcb1a/b−/− mice (Padj <
0.01) than in wild-type mice but was not increased in Abcg2−/
− mice (Padj = 0.14) (Table 1). After pretreatment with
Fig. 1 Reaction scheme for the synthesis of [18F]AVT-011
Fig. 2 [18F]AVT-011 is a substrate of mouse ABCB1 and ABCG2, as
assessed by PET imaging. a Representative summation images of
radiotracer uptake in the brain (% injected dose, (ID)/g) after
intravenous injection of [18F]AVT-011 in wild-type or transgenic mice
lacking Abcb1a/b or Abcg2. b Time-activity curves in all strains of mice
at baseline conditions and c after pharmacological inhibition of ABCB1
with 15 mg/kg tariquidar (TQR). Symbols represent mean ± SD from n =
5mice/strain, with the exception ofAbcg2−/− after inhibition (n = 2). Inset
shows time-activity curve ranging from 0 to 1 %ID/g
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tariquidar (15 mg/kg), brain uptake of [18F]AVT-011 in-
creased 3-fold in wild-type mice (Padj < 0.001) and 8-fold in
Abcg2−/− mice (Padj < 0.001), relative to baseline values.
However, uptake did not significantly increase in Abcb1a/
b−/− mice after inhibition (Padj = 0.78; Fig. 2c and Table 1).
[18F]AVT-011 is minimally metabolized
and predominantly undergoes hepatobiliary
excretion
We then assessed the radiometabolism and biodistribution of
[18F]AVT-011. At 30 min after injection of [18F]AVT-011, the
percentage of intact parent radiotracer measured in mouse
liver was 93.3 ± 2.8% in wild-type mice (n = 3), 93.6 ±
1.7% in Abcb1a/b−/− mice (n = 4), and 94.0 ± 1.4% in
Abcg2−/− mice (n = 2), with 84.0 ± 5.0% of radioactivity
recovered from liver tissue. Apart from the blood-brain barri-
er, ABCB1 and ABCG2 are also expressed in the kidneys,
liver, small intestine, and lungs [11]. Analysis of organ uptake
from PET scans revealed that the small intestine, spleen, liver,
and kidney had the highest values in all three strains of mice
(Table 2). Uptake in organs was not significantly different
among the strains, except in the spleen and small intestine.
In the spleen, radioactivity concentrations were 27% higher
in Abcb1a/b−/−mice (Padj = 0.01) and 51% lower in Abcg2
−/−
mice (Padj < 0.001) than in wild-type mice. In the small intes-
tine, concentrations were 60% and 75% lower in Abcb1a/b−/−
and Abcg2−/− mice (Padj < 0.001) than in wild-type mice. Ex
vivo biodistribution measurements also showed highest up-
take in the hepatobiliary system and the kidney of all three
strains (Supplemental Table 1). Uptake was also 67% higher
in the lungs of Abcb1a/b−/− and Abcg2−/−mice (Padj < 0.001)
than in those of wild-type mice (Supplemental Table 1).
Although brain uptake was not statistically different among
groups in ex vivo biodistribution measurements (likely be-
cause ex vivo data lacked statistical power due to smaller
group sizes), effect sizes among groups were similar to those
obtained in vivo.
[18F]AVT-011 can image ABCB1 function
in chemotherapy-resistant tumors
To measure ABCB1 function in chemotherapy-resistant tu-
mors, we imaged three groups of mice with [18F]AVT-011
before and after tariquidar treatment (Fig. 3a, b) and with
[18F]FDG for anatomical localization. Wild-type mice were
implanted orthotopically with breast tumors comprising three
levels of Abcb1a/b expression and ABCB1 protein levels
(Supplemental Fig. 2) found in clinical tumors [1]: basal, in-
termediate (3-fold increase in Abcb1a/b), or high (~ 521-fold
increase in Abcb1a/b). These tumor grafts were derived from
Brca1−/−;p53−/− mouse breast tumors that were previously
responsive to chemotherapy (basal) or developed resistance
after several cycles of treatment with doxorubicin
(intermediate) or with pegylated liposomal doxorubicin [26].
After injection of [18F]AVT-011, radioactivity concentrations
(%ID/g) in tumors peaked within the first 5 min and reached a
plateau by 45 min (Fig. 3c, d). Tumor uptake of [18F]AVT-
011, measured as AUC of %ID/g*min from 5–42.5 min, was
15% lower in the intermediate group (Padj = 0.10) and 32%
lower in the high ABCB1–expressing group (P < 0.001) than
in the basal group (Fig. 4a). In contrast, tumor uptake of
[18F]FDG, measured as %ID/g at 60 min after injection, was
not significantly different among the three groups
(intermediate vs basal, Padj = 0.92; high vs basal, Padj =
0.16; Fig. 4b).
Radioactivity concentrations in the tumor increased in all
groups following a bolus injection of tariquidar (15 mg/kg)
administered 45 min after injection of [18F]AVT-011 (Fig. 3c).
Relative to tumor uptake at 45 min, tumor uptake (%ID/g) at
Table 1 Brain uptake of radioactivity measured with PET in three
strains of mice after injection of [18F]AVT-011 at baseline and after
pharmacological inhibition of ABCB1A/B
Brain uptake (%ID/g*min)
Condition Wild-type Abcb1a/b−/− Abcg2−/−
Baseline 0.37 ± 0.08 0.73 ± 0.17** 0.53 ± 0.09
After TQR 1.08 ± 0.15 0.81 ± 0.11* 4.19 ± 0.28***
Brain uptake (%ID/g*min) was quantified as the area under the time-
activity curve from 5 to 120 min after injection of [18 F]AVT-011.
Tariquidar (TQR) was administered 30 min prior to injection of the ra-
diotracer. Data represent mean ± SD from n = 5 mice/group; n = 2 for
Abcg2−/− after tariquidar. *Padj < 0.05, **Padj < 0.01, and ***Padj <
0.001, against wild-type, using two-way ANOVA with Dunnett’s
correction
Table 2 Uptake of radioactivity measured with PET in various organs
from three strains of mice after injection of [18F]AVT-011
Organ uptake (%ID/g*min)
Organ Wild-type Abcb1a/b−/− Abcg2−/−
Bladder 11.2 ± 1.6 9.3 ± 3.1 9.6 ± 2.0
Heart 1.7 ± 0.2 2.0 ± 0.1 1.9 ± 0.1
Kidney 12.5 ± 0.9 12.2 ± 1.0 11.7 ± 0.3
Liver 14.7 ± 0.8 13.1 ± 0.6 18.0 ± 0.7
Muscle 1.3 ± 0.1 1.8 ± 0.1 2.0 ± 0.2
Small intestine 36.3 ± 10.6 14.5 ± 0.7*** 9.0 ± 1.4***
Spleen 23.5 ± 7.0 29.9 ± 8.7* 11.5 ± 1.8***
Organ uptake (%ID/g*min) was quantified as the area under the time-
activity curve from 5 to 120 min after injection of [18 F]AVT-011. Data
represent mean ± SD from n = 5 mice/group. *Padj < 0.05 and ***Padj <
0.001, against wild-type, using two-way ANOVA with Dunnett’s
correction
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Fig. 3 [18F]AVT-011 can detect ABCB1 function in an orthotopic mouse
model of breast cancer, as assessed by PET imaging. a Schematic of
dynamic PET study performed in tumor-bearing mice. b Summation
PET images of [18F]AVT-011 from 0 to 45 min (baseline) and from 45
to 90 min (tariquidar, TQR) after radiotracer injection in basal and high
ABCB1–expressing tumor groups. Color bar represents radioactivity
concentration (%ID/g), set from 0.2 to 2. Anatomical structures are
highlighted with white broken lines and labeled with arrows. c Time-
activity curves in tumors expressing basal, intermediate, and high levels
of ABCB1. Tariquidar (TQR, 15 mg/kg) was injected intravenously at 45
min. Symbols represent mean ± SD from n = 6 mice (basal tumors), n = 7
mice (intermediate-ABCB1 tumors), and n = 5 (high-ABCB1 tumors). d
Time-activity curves in tumors expressing basal and high levels of
ABCB1 not treated with tariquidar. Symbols represent mean ± SD from




































































Fig. 4 [18F]AVT-011 can discriminate tumors expressing basal and high
levels of ABCB1, while [18F]FDG cannot. a Tumor uptake of [18F]AVT-
011, measured as the area under the curve of%ID/g from 5 to 42.5min, in
tumors expressing basal (n = 9), intermediate (n = 7), or high (n = 10)
levels of ABCB1. b Tumor uptake of [18F]FDG, measured as %ID/g at
60 min after injection, in the same tumors imaged 1 day prior to
[18F]AVT-011. ***P < 0.001 by one-way ANOVA followed by
Dunnett’s multiple comparisons test
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90 min increased by 27.5 ± 9.7% in the basal group, by 31.2 ±
13.3% in the intermediate group, and by 40.9 ± 3.7% in the
high ABCB1–expressing group. The percentage increase in
the high ABCB1–expressing group was significantly higher
than in the basal group (Padj = 0.02). By contrast, the increase
in tumor uptake between 45 and 90 min in animals not treated
with tariquidar (Fig. 3d) was 10.4 ± 10.6% in the basal group
(n = 4 mice) and 5.4 ± 12.6% in the high ABCB1–expressing
group (n = 5 mice). The percentage increase in muscle uptake
(%ID/g) at 90 min after radiotracer injection relative to muscle
uptake at 45 min (before tariquidar administration) was not
significantly different between animals injected with
tariquidar mid-scan (24.1 ± 5.0 %) and those not injected with
tariquidar mid-scan (29.1 ± 2.9%, Supplemental Fig. 3). At
the end of the scan (i.e., at 90 min), intact [18F]AVT-011 in
mouse plasma was 83.8 ± 1.9% in the basal group, 54.1 ±
14.8% in the intermediate group (Padj = 0.02), and 85.7 ±
2.6% in the high ABCB1–expressing group (Padj = 0.83).
Discussion
Substrate selectivity of [18F]AVT-011
We characterized the pharmacological properties of [18F]AVT-
011and tested its utility as a radiotracer for imaging ABC
transporter function in MDR tumors. [18F]AVT-011 is a sub-
strate of mouse ABCB1A/B, evidenced by the 2-fold en-
hanced uptake in the brains of Abcb1a/b−/− mice relative to
wild-type mice at baseline, and by the increased uptake in the
brains of wild-type and Abcg2−/− mice after administration of
tariquidar, which predominantly inhibited ABCB1 and not
ABCG2 at the employed dose of 15 mg/kg [22, 28]. The
radiotracer also appears to be a substrate of mouse ABCG2,
as evidenced by the significantly higher increase in brain up-
take of [18F]AVT-011 following ABCB1 inhibition in Abcg2−/
− mice (8-fold) than in wild-type mice (3-fold). These results
are consistent with functional redundancy between ABCB1A/
B and ABCG2 at the blood-brain barrier in limiting brain
uptake of dual ABCB1/ABCG2 substrates [29], and with pre-
vious reports on the brain uptake of other ABC transporter
substrate radiotracers [30, 31]. While [18F]AVT-011’s lack of
selectivity may be undesirable for imaging transporter func-
tion in certain pathophysiological conditions [11], its dual
substrate property may be beneficial for imaging MDR medi-
ated by ABC transporters in tumors because ABCB1 and
ABCG2 are often co-expressed [1], and can independently
and additively contribute to MDR [32].
While the higher brain uptake of [18F]AVT-011 in wild-
type and Abcg2−/− mice after tariquidar administration could
have resulted from changes in perfusion, this possibility is
unlikely for two reasons. First, administration of tariquidar
was shown to have no effect on cerebral blood flow in non-
human primates and humans, as measured by [15O]H2O PET
[33, 34], suggesting that it will likely not affect cerebral blood
flow in mice. Second, the lack of changes in brain uptake of
[18F]AVT-011 in tariquidar-treated Abcb1a/b−/− mice argues
against the possibility that tariquidar exerted an effect on per-
fusion and that brain uptake of [18F]AVT-011 was perfusion-
dependent. The increased brain uptake of [18F]AVT-011 in
wild-type and Abcg2−/− mice after tariquidar administration
therefore is most likely a result of ABCB1 inhibition and not
enhanced perfusion.
Imaging ABCB1 transporter function in tumors
with [18F]AVT-011
Using PET imaging, we demonstrated that [18F]AVT-011 can
measure ABCB1 function in a mouse model of drug-resistant
breast tumors. This previously described tumor model [24,
25], in which tumors from Brca1−/−;p53−/− mice are
transplanted into wild-type mice, recapitulates clinically ob-
served MDR. That is, Brca1−/−;p53−/− tumors show initial
sensitivity to chemotherapy, but eventually acquire resistance
to docetaxel, doxorubicin, topotecan, and/or olaparib with
concomitant increases in Abcb1a/b expression [24, 35] to
the levels found in clinical tumors [1]. In this study,
[18F]AVT-011 could discriminate between tumors expressing
basal and high levels of ABCB1, as evidenced by the 32%
reduced uptake in tumors with high levels of ABCB1 and by
the 40% increase in tumor uptake following tariquidar admin-
istration. Since the percentage increase in radiotracer uptake in
muscle was not significantly different between mice that re-
ceived tariquidar mid-scan and those that did not, the en-
hanced uptake after tariquidar administration in tumors was
most likely a result of ABCB1 inhibition and not enhanced
perfusion. Tumor uptake of [18F]FDG was also not signifi-
cantly different between basal and high groups, making it
unlikely that other factors such as tumor vascularization could
account for the differences in tumor uptake of [18F]AVT-011.
Lastly, differences in radiotracer metabolism could not explain
these differences, as the percentage of unchanged [18F]AVT-
011 was not different between mice harboring tumors with
basal levels of ABCB1 and those with high levels. Together,
these results indicate that [18F]AVT-011 images ABCB1-
mediated MDR in tumors, although it may also recognize
other transporter-mediated MDR (e.g., by ABCG2) in tumors.
While the radiotracer discriminated between tumors ex-
pressing basal and high levels of ABCB1, it did not show a
significant difference between basal and intermediate levels of
ABCB1. What would be the minimum threshold of transport-
er expression needed for a radiotracer to be useful in detecting
transporter-mediated MDR in vivo? The answer to this ques-
tion is important for cancer treatment because profiling of
mRNA expression has been recommended as a screening tool
for MDR in the clinic [1]. In our study, relative to values in the
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basal group, Abcb1a/bmRNA expression was ~ 3-fold higher
and ABCB1 protein levels were ~ 4-fold higher in the inter-
mediate tumor group, while Abcb1a/bmRNA expression was
~ 521-fold higher and ABCB1 protein levels were ~ 13-fold
higher in the high ABCB1–expressing group. By PET, we
measured a ~ 15% difference in ABCB1 function between
the basal and intermediate-ABCB1 groups, and a ~ 32% dif-
ference between the basal and high ABCB1–expressing
groups. This result is similar to the 50% reduced uptake of
[11C]verapamil in drug-resistant tumors [18] and to the 35%
reduced uptake of [99mTc]sestamibi in drug-resistant tumors
expressing 8-fold higher ABCB1 protein levels [36]. Because
function does not appear to correlate linearly with expression,
one caveat for using imaging is that the threshold of sensitivity
for detecting ABCB1 function in tumors is currently un-
known. Nevertheless, despite the lower sensitivity of PET in
distinguishing basal versus high-ABCB1 groups compared
with mRNA profiling, PET imaging could be clinically ad-
vantageous for detecting MDR because it is non-invasive and
can be used in whole body, longitudinal studies.
Comparison of [18F]AVT-011 with other radiotracers
for imaging ABC transporters in tumors
How does [18F]AVT-011 compare with the other substrate
radiotracers, including [99mTc]sestamibi, [11C]verapamil, and
[18F]fluoropaclitaxel, used to image MDR mediated by ABC
transporters in tumors? In terms of substrate selectivity, our
results show that [18F]AVT-011 is likely a substrate of both
ABCB1 and ABCG2, while [99mTc]sestamibi is transported
by both ABCB1 and multidrug resistance–associated protein
1 (ABCC1) [37], and (R)-[11C]verapamil is selective for
ABCB1 over ABCG2 and ABCC1 [38]. [18F]AVT-011 and
[99mTc]sestamibi therefore offer the possibility to probe differ-
ent biological mechanisms of MDR, although ABCB1 and
ABCG2 tend to be co-expressed in tumors with MDR [1].
[11C]Tariquidar is another radiotracer that was developed to
image ABCB1 density [21]. The radiotracer displayed mod-
erately higher uptake in a mouse xenograft tumor model over-
expressing ABCB1 than in ABCB1-negative tumors [20],
presumably due to ABCB1 binding. However, conflicting ev-
idence exists whether this radiotracer is transported by
ABCB1 [22, 23], which may confound PET measurements
of ABCB1 density and/or function. In contrast, [18F]AVT-
011 showed lower uptake in mouse orthotopic tumors ex-
pressing clinically relevant levels of ABCB1 than in those
with basal levels of ABCB1, and showed increased tumor
uptake after ABCB1 inhibition, consistent with the behavior
of an ABCB1 substrate.
In terms of pharmacokinetics, [18F]AVT-011 has stable up-
take in tumors, reaching a plateau within 15 min after injec-
tion. This pattern of uptake has also been observed for other
ABCB1 radiotracers [18, 36], and may be a result of
mitochondrial [39] or lysosomal trapping [40]. While the up-
take at later time points may be non-specific, the initial uptake
is likely to reflect the activity of ABCB1 (and likely ABCG2)
and therefore would only require short PET scans for quanti-
tation [18]. [18F]AVT-011 is metabolically stable, as evi-
denced by < 10% metabolism in mouse liver. In this sense,
the radiotracer is advantageous because [11C]verapamil and
[18F]fluoropaclitaxel are metabolized > 50% within 30–40
min [17, 18]. However, because its primary mode of excretion
is through the hepatobiliary system, [18F]AVT-011 would not
be useful in imaging tumors located in organs such as the liver
and gastrointestinal tract (whose cancers have high ABCB1
and ABCG2 expressions) because the high baseline values
of uptake in these organs would make it difficult to distinguish
uptake in tumor versus normal tissue [1].
Potential clinical utility of [18F]AVT-011
Given its properties, [18F]AVT-011 would likely be useful for
screening an important mechanism of drug resistance (i.e.,
ABC transporter-mediated) in select cancers, such as breast
tumors or lymph node metastasis. Detecting ABC transporter
function in patients using a generic radiotracer such as
[18F]AVT-011 may also offer clinicians the ability to select
or avoid chemotherapeutics that are substrates for ABCB1/
ABCG2. Furthermore, because of the 18F label, the radiotracer
could potentially be distributed from a central production site
to different hospitals without a radiochemistry facility, thereby
allowing broader clinical use.
Conclusion
We evaluated the pharmacological properties of a new PET
radiotracer [18F]AVT-011. Using PET imaging in mice, we
found that it is a substrate for mouse ABCB1 and ABCG2,
is minimally metabolized, and undergoes primarily
hepatobiliary excretion. [18F]AVT-011 PET measures
ABCB1 function in tumors expressing clinically relevant
levels of ABCB1 and could potentially be used to detect
MDR in select human cancers.
Acknowledgments We thank Johann Stanek, Thomas Filip, Michael
Sauberer, and Mathilde Löbsch (AIT) for their assistance in tumor imag-
ing experiments; Nora Kucsma for technical assistance; and Waldemar
Ladno (UCLA) for assistance in transgenic mice imaging.
Contributions PK, SD, OL, GS, and DM designed and supervised ex-
periments. AF, TW, SM, JL, JC, TF, and RMV conducted experiments.
PK, TW, SM, and OL analyzed data and performed statistical analysis.
PK and OL wrote the manuscript, with input and revisions from all
authors.
Eur J Nucl Med Mol Imaging
Funding information Open access funding provided by Karolinska
Institute. The study was supported by Avaant Imaging and by the
Austrian Science Fund FWF (grants F 3513-B01 and SFB35).
Compliance with ethical standards
Conflict of interest PK and SD served as scientific consultants for
Avaant Imaging, with no financial interest and/or stock. DM is the
CEO. RMV and the Regents of the University of California own shares
in Sofie Inc., which manufactures the ELIXIS synthesizer. AF, TW, SM,
JC, TF, JTL, GS, and OL declare no conflict of interest.
Ethical approval All applicable international, national, and/or institu-
tional guidelines for the care and use of animals were followed. All
procedures performed in studies involving animals were in accordance
with the ethical standards of the institutions at which the studies were
conducted (UCLA Chancellor’s Animal Research Committee, protocol
no. 2014-012; Amt der Niederösterreichischen Landesregierung (permit
number: LF1-TVG-48/030-2017)). This article does not contain any stud-
ies with human participants performed by any of the authors.
Open Access This article is distributed under the terms of the Creative
Commons At t r ibut ion 4 .0 In te rna t ional License (h t tp : / /
creativecommons.org/licenses/by/4.0/), which permits unrestricted use,
distribution, and reproduction in any medium, provided you give
appropriate credit to the original author(s) and the source, provide a link
to the Creative Commons license, and indicate if changes were made.
References
1. Robey RW, Pluchino KM, Hall MD, Fojo AT, Bates SE, Gottesman
MM. Revisiting the role of ABC transporters in multidrug-resistant
cancer. Nat Rev Cancer. 2018;18:452–64.
2. Szakács G, Paterson J, Ludwig J, Booth-Genthe C, Gottesman M.
Targeting multidrug resistance in cancer. Nat Rev Drug Discov.
2006;5:219–34.
3. Ho MM, Hogge DE, Ling V. MDR1 and BCRP1 expression in
leukemic progenitors correlates with chemotherapy response in
acute myeloid leukemia. Exp Hematol. 2008;36:433–42.
4. Bartholomae S, Gruhn B, Debatin K-M, Zimmermann M, Creutzig
U, Reinhardt D, et al. Coexpression ofmultiple ABC-transporters is
strongly associated with treatment response in childhood acute my-
eloid leukemia. Pediatr Blood Cancer. 2016;63:242–7.
5. Marzac C, Garrido E, Tang R, Fava F, Hirsch P, De Benedictis C,
et al. ATP binding cassette transporters associated with
chemoresistance: transcriptional profiling in extreme cohorts and
their prognostic impact in a cohort of 281 acute myeloid leukemia
patients. Haematologica. 2011;96:1293–301.
6. Trock BJ, Leonessa F, Clarke R. Multidrug resistance in breast
cancer: a meta-analysis of MDR1/Pgp170 expression and its pos-
sible functional significance. J Natl Cancer Inst. 1997;89:917–31.
7. Patel C, Stenke L, Varma S, LindbergML, BjörkholmM, Sjöberg J,
et al. Multidrug resistance in relapsed acute myeloid leukemia: ev-
idence of biological heterogeneity. Cancer. 2013;119:3076–83.
8. van den Heuvel-Eibrink M, Wiemer E, Prins A, Meijerink J,
Vossebeld P, van der Holt B, et al. Increased expression of the breast
cancer resistance protein (BCRP) in relapsed or refractory acute
myeloid leukemia (AML). Leukemia. 2002;16:833–9.
9. Suwa H, Ohshio G, Arao S, Imamura T, Yamaki K,Manabe T, et al.
Immunohistochemical localization of P-glycoprotein and expres-
sion of the multidrug resistance-1 gene in human pancreatic cancer:
relevance to indicator of better prognosis. Jpn J Cancer Res.
1996;87:641–9.
10. Mohelnikova-Duchonova B, Brynychova V, Oliverius M, Honsova
E, Kala Z,MuckovaK, et al. Differences in transcript levels of ABC
transporters between pancreatic adenocarcinoma and nonneoplastic
tissues. Pancreas. 2013;42:707–16.
11. Kannan P, John C, Zoghbi SS, Halldin C, Gottesman MM, Innis
RB, et al. Imaging the function of P-glycoprotein with radiotracers:
pharmacokinetics and in vivo applications. Clin Pharmacol Ther.
2009;86:368–77.
12. Karaszi E, Jakab K, Homolya L, Szakacs G, Hollo Z, Telek B, et al.
Calcein assay for multidrug resistance reliably predicts therapy re-
sponse and survival rate in acute myeloid leukaemia. Br J
Haematol. 2001;112:308–14.
13. Takamura Y, Miyoshi Y, Taguchi T, Noguchi S. Prediction of che-
motherapeutic response by Technetium 99m–MIBI scintigraphy in
breast carcinoma patients. Cancer. 2001;92:232–9.
14. Del Vecchio S, Ciarmiello A, Pace L, Potena MI, Carriero MV,
Mainolfi C, et al. Fractional retention of 99m-Tc-sestamibi as an
index of P-glycoprotein expression in untreated breast cancer pa-
tients. J Nucl Med. 1997;38:1348–51.
15. van Leeuwen FWB, Buckle T, Kersbergen A, Rottenberg S,
Gilhuijs KGA. Noninvasive functional imaging of P-
glycoprotein-mediated doxorubicin resistance in a mouse model
of hereditary breast cancer to predict response, and assign P-gp
inhibitor sensitivity. Eur J Nucl Med Mol Imaging. 2009;36:406–
12.
16. Ciarmiello A, Del Vecchio S, Silvestro P, Potena MI, Carriero MV,
Thomas R, et al. Tumor clearance of technetium 99m-sestamibi as a
predictor of response to neoadjuvant chemotherapy for locally ad-
vanced breast cancer. J Clin Oncol. 1998;16:1677–83.
17. Kurdziel KA, Kalen JD, Hirsch JI, Wilson JD, Agarwal R, Barrett
D, et al. Imaging multidrug resistance with 4-18F-fluoropaclitaxel.
Nucl Med Biol. 2007;34:823–31.
18. Hendrikse NH, de Vries EG, Eriks-Fluks L, van der Graaf WT,
Hospers GA, Willemsen AT, et al. A new in vivo method to study
P-glycoprotein transport in tumors and the blood-brain barrier.
Cancer Res. 1999;59:2411–6.
19. Agrawal M, Abraham J, Balis FM, Edgerly M, Stein WD, Bates S,
et al. Increased 99mTc-sestamibi accumulation in normal liver and
drug-resistant tumors after the administration of the glycoprotein
inhibitor, XR9576. Clin Cancer Res. 2003;9:650–6.
20. Wanek T, Kuntner C, Bankstahl JP, Bankstahl M, Stanek J,
Sauberer M, et al. A comparative small-animal PET evaluation of
11C-tariquidar, 11C-elacridar and (R)-11C-verapamil for detection
of P-glycoprotein-expressing murine breast cancer. Eur J Nucl Med
Mol Imaging. 2012;39:149–59.
21. Bauer F, Kuntner C, Bankstahl JPJ, Wanek T, Bankstahl M, Stanek
J, et al. Synthesis and in vivo evaluation of [11C]tariquidar, a pos-
itron emission tomography radiotracer based on a third-generation
P-glycoprotein inhibitor. Bioorg Med Chem. 2010;18:5489–97.
22. Bankstahl JP, Bankstahl M, Römermann K, Wanek T, Stanek J,
Windhorst AD, et al. Tariquidar and elacridar are dose-
dependently transported by P-glycoprotein and Bcrp at the blood-
brain barrier: a small-animal positron emission tomography and
in vitro study. Drug Metab Dispos. 2013;41:754–62.
23. Weidner LD, Fung KL, Kannan P, Moen JK, Kumar JS, Mulder J,
et al. Tariquidar is an inhibitor and not a substrate of human and
mouse P-glycoprotein. Drug Metab Dispos. 2016;44:275–82.
24. Rottenberg S, Nygren AOH, Pajic M, van Leeuwen FWB, van der
Heijden I, van de Wetering K, et al. Selective induction of chemo-
therapy resistance ofmammary tumors in a conditional mousemod-
el for hereditary breast cancer. Proc Natl Acad Sci U SA. 2007;104:
12117–22.
25. Füredi A, Tóth S, Szebényi K, Pape VFS, Türk D, Kucsma N, et al.
Identification and validation of compounds selectively killing
Eur J Nucl Med Mol Imaging
resistant cancer: delineating cell line–specific effects from P-glyco-
protein–induced toxicity. Mol Cancer Ther. 2017;16:45–56.
26. Füredi A, Szebényi K, Tóth S, Cserepes M, Hámori L, Nagy V,
et al. Pegylated liposomal formulation of doxorubicin overcomes
drug resistance in a genetically engineered mouse model of breast
cancer. J Control Release. 2017;261:287–96.
27. Loening AM, Gambhir SS. AMIDE: a free software tool for
multimodality medical image analysis. Mol Imaging. 2003;2:
131–7.
28. Kühnle M, Egger M, Müller C, Mahringer A, Bernhardt G, Fricker
G, et al. Potent and selective inhibitors of breast cancer resistance
protein (ABCG2) derived from the p-glycoprotein (ABCB1) mod-
ulator tariquidar. J Med Chem. 2009;52:1190–7.
29. Kodaira H, Kusuhara H, Ushiki J, Fuse E, Sugiyama Y. Kinetic
analysis of the cooperation of P-glycoprotein (P-gp/Abcb1) and
breast cancer resistance protein (Bcrp/Abcg2 ) in limiting the brain
and testis penetration of erlotinib. J Pharmacol Exp Ther. 2010;333:
788–96.
30. Kawamura K, Yamasaki T, Konno F, Yui J, Hatori A, Yanamoto K,
et al. Synthesis and in vivo evaluation of 18F-fluoroethyl GF120918
and XR9576 as positron emission tomography probes for assessing
the function of drug efflux transporters. Bioorg Med Chem.
2011;19:861–70.
31. Dörner B, Kuntner C, Bankstahl JP, Wanek T, Bankstahl M, Stanek
J, et al. Radiosynthesis and in vivo evaluation of 1-
[18F]fluoroelacridar as a positron emission tomography tracer for
P-glycoprotein and breast cancer resistance protein. Bioorg Med
Chem. 2011;19:2190–8.
32. Robinson AN, Tebase BG, Francone SC, Huff LM, Kozlowski H,
Cossari D, et al. Co-expression of ABCB1 andABCG2 in a cell line
model reveals both independent and additive transporter function.
Drug Metab Dispos. 2019.
33. Liow JS, Kreisl W, Zoghbi SS, Lazarova N, Seneca N, Gladding
RL, et al. P-glycoprotein function at the blood-brain barrier imaged
using 11C-N-desmethyl-loperamide in monkeys. J Nucl Med.
2009;50:108–15.
34. Kreisl WC, Liow J-SS, Kimura N, Seneca N, Zoghbi SS, Morse
CL, et al. P-glycoprotein function at the blood-brain barrier in
humans can be quantified with the substrate radiotracer 11C-N-
desmethyl-loperamide. J Nucl Med. 2010;51:559–66.
35. Pajic M, Iyer JK, Kersbergen A, Van Der Burg E, Nygren AOH,
Jonkers J, et al. Moderate increase in Mdr1a/1b expression causes
in vivo resistance to doxorubicin in a mouse model for hereditary
breast cancer. Cancer Res. 2009;69:6396–404.
36. Piwnica-Worms D, Chiu ML, Budding M, Kronauge JF, Kramer
RA, Croop JM. Functional imaging of multidrug-resistant P-glyco-
protein with an organotechnetium complex. Cancer Res. 1993;53:
977–84.
37. Hendrikse NH, Franssen EJ, van der GraafWT,Meijer C, Piers DA,
VaalburgW, et al. 99mTc-sestamibi is a substrate for P-glycoprotein
and the multidrug resistance-associated protein. Br J Cancer.
1998;77:353–8.
38. RömermannK,Wanek T, BankstahlM, Bankstahl JP, FedrowitzM,
Müller M, et al. (R)-11C-verapamil is selectively transported by
murine and human P-glycoprotein at the blood-brain barrier, and
not by MRP1 and BCRP. Nucl Med Biol. 2013;40:873–8.
39. Del Vecchio S, Zannetti A, Aloj L, SalvatoreM.MIBI as prognostic
factor in breast cancer. Q J Nucl Med. 2003;47:46–50.
40. Kannan P, Brimacombe KR, Kreisl WC, Liow J-S, Zoghbi SS, Telu
S, et al. Lysosomal trapping of a radiolabeled substrate of P-
glycoprotein as a mechanism for signal amplification in PET. Proc
Natl Acad Sci U S A. 2011;108:2593–8.
Publisher’s note Springer Nature remains neutral with regard to jurisdic-
tional claims in published maps and institutional affiliations.
Eur J Nucl Med Mol Imaging
